Results 221 to 230 of about 24,478 (263)
Some of the next articles are maybe not open access.
Journal of Antimicrobial Chemotherapy, 2023
Abstract Objectives Caspofungin is an echinocandin antifungal agent that inhibits synthesis of glucan required for the fungal cell wall. Resistance is mediated by mutation of Fks1 glucan synthase, among which S645P is the most common resistance-associated polymorphism.
Maxime Lefranc +4 more
openaire +2 more sources
Abstract Objectives Caspofungin is an echinocandin antifungal agent that inhibits synthesis of glucan required for the fungal cell wall. Resistance is mediated by mutation of Fks1 glucan synthase, among which S645P is the most common resistance-associated polymorphism.
Maxime Lefranc +4 more
openaire +2 more sources
Drugs of Today, 2002
Available systemically effective antifungal agents for the treatment of invasive fungal infections are few. With the increasing recognition of a need for newer antifungal drugs, caspofungin has been introduced as the first member of a new class of compounds called echinocandins.
P H, Chandrasekar, E K, Manavathu
openaire +2 more sources
Available systemically effective antifungal agents for the treatment of invasive fungal infections are few. With the increasing recognition of a need for newer antifungal drugs, caspofungin has been introduced as the first member of a new class of compounds called echinocandins.
P H, Chandrasekar, E K, Manavathu
openaire +2 more sources
The first echinocandin: caspofungin
Mycoses, 2002Summary. The antifungal agent caspofungin is the first echinocandin that has been approved in the US and in Europe for treatment of invasive aspergillosis in adult patients who are refractory to or intolerant of conventional amphotericin B, its lipid‐based formulations, and/or itraconazole.
Karina Schmitz +2 more
openaire +3 more sources
APMIS, 2006
Disseminated candidiasis is relatively common in immunocompromised patients. The treatment protocol of these patients usually includes broad‐spectrum antibiotics and also emprical antifungals initiated due to unresponsiveness to antibiotics. In this study the efficacies of caspofungin and meropenem – separately and together – in mice with disseminated ...
Serdar Filiz +5 more
openaire +3 more sources
Disseminated candidiasis is relatively common in immunocompromised patients. The treatment protocol of these patients usually includes broad‐spectrum antibiotics and also emprical antifungals initiated due to unresponsiveness to antibiotics. In this study the efficacies of caspofungin and meropenem – separately and together – in mice with disseminated ...
Serdar Filiz +5 more
openaire +3 more sources
Journal of Clinical Microbiology, 2003 Caspofungin in Pediatric Patients
Pediatric Health, 2008Invasive fungal infections have emerged as one of the most significant complications in severely immunocompromised pediatric patients, such as children suffering from hematological malignancies or children undergoing hematopoietic stem cell transplantation. In addition, neonates, in particular preterm infants, are at risk for invasive mycoses. Owing to
Thomas Lehrnbecher, Andreas H. Groll
openaire +2 more sources
The pharmacology and clinical use of caspofungin
Expert Opinion on Drug Metabolism & Toxicology, 2007Caspofungin was the first echinocandin to be licensed for the treatment of invasive fungal infections. Caspofungin has in vitro and in vivo activity against Candida spp. and Aspergillus spp., which constitute the majority of medically important opportunistic fungal pathogens.
Hope, William W. +2 more
openaire +4 more sources
Expert Review of Anti-infective Therapy, 2005
The echinocandins are a novel class of antifungal agents that have come into use over the past 10 years. The mechanism of action of these lipopeptide agents is via noncompetitive inhibition of the synthesis of 1,3-beta-glucans, which are fungal cell wall constituents. All agents of this class are only available in an intravenous formulation.
openaire +3 more sources
The echinocandins are a novel class of antifungal agents that have come into use over the past 10 years. The mechanism of action of these lipopeptide agents is via noncompetitive inhibition of the synthesis of 1,3-beta-glucans, which are fungal cell wall constituents. All agents of this class are only available in an intravenous formulation.
openaire +3 more sources
Caspofungin: An echinocandin antifungal agent
Clinical Therapeutics, 2002The mainstays of treatment for nosocomial fungal infections have been amphotericin B and azole derivatives. Caspofungin acetate is a new echinocandin antifungal agent with a mechanism of action that targets a structural component of the fungal cell wall.This article describes the pharmacologic properties and potential clinical usefulness of caspofungin.
Horatio B. Fung +2 more
openaire +3 more sources
Caspofungin Functionalized Polymethacrylates with Antifungal Properties
Biomacromolecules, 2020We describe the synthesis of hydrophilic poly(poly(ethylene glycol) methyl ether methacrylate) (PmPEGMA) and hydrophobic poly(methyl methacrylate) (PMMA) caspofungin conjugates by a post-polymerization modification of copolymers containing 10 mol % pentafluorophenyl methacrylate (PFPMA), which were obtained via reversible addition-fragmentation chain ...
Julien Alex +11 more
openaire +2 more sources